Overview
TNYA market data
Price History
TNYA price chart · 3M
- O
- 0.702500
- H
- 0.713700
- L
- 0.698400
- C
- 0.700100
- Vol
- 21,983.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.70
- Previous Close
- $0.70
- Day High
- $0.71
- Day Low
- $0.70
- 52 Week High
- $1.15
- 52 Week Low
- $0.66
- 7 Day Return
- +1.35%
- 30 Day Return
- -7.15%
- 90 Day Return
- -20.59%
- 1 Year Return
- +5.56%
- Daily Notional Volume
- $15.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.59 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.94 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.53 – $2.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $164.4M · P/B 1.25.
Company News
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M EstimateBenzinga · Aug 5, 2026, 10:39 PM
8-K filing — Tenaya Therapeutics, Inc. (TNYA)SEC EDGAR · Jul 2, 2026, 9:00 PM
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13Benzinga · Jun 29, 2026, 12:40 PM
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3Benzinga · Jun 2, 2026, 8:32 PM